Proteinuria Therapeutics Market by Product and Geography - Global Forecast & Analysis 2022-2028
Global Proteinuria Therapeutics Market: About this market
proteinuria therapeutics market analysis considers sales from ACE inhibitors, ARBs, and other therapeutic products. Our analysis also considers the sales of proteinuria therapeutics in Asia, Europe, North America, and ROW. In 2018, the ACE inhibitors segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the prevention of an enzyme in the body from producing angiotensin II, which narrows the blood vessels will play a significant role in the ACE inhibitors segment to maintain its market position. Also, our global proteinuria therapeutics market report looks at factors such as recent approvals and launch of advanced urinalysis diagnostic kits, increasing prevalence of associated risk factors, and growing geriatric population. However, lack of curative therapies, adverse effects of available therapeutics, and stringent regulations may hamper the growth of the proteinuria therapeutics industry over the forecast period.
Global Proteinuria Therapeutics Market: Overview
Increasing prevalence of associated risk factors
Proteinuria is a condition in which urine contains an abnormal amount of protein. This condition can be a sign of damage within the kidneys and CKD: the latter can result from diabetes as well as high blood pressure hypertension. Proteinuria can be caused by diseases that do not involve the kidneys, such as multiple myeloma and others, such as, AIDS, lupus, and rheumatoid arthritis, which also cause inflammation in the kidneys. Globally, the prevalence of all these diseases and infections is very high and is increasing continuously. This multifactorial etiology of the condition increases the demand for treatment options and, thus, drives the growth of the market at a CAGR of almost 3% during the forecast period.
Introduction of smartphone-based diagnosis and treatment
Advances in technology help in increasing the adherence of patients to treatment and, thus, obtain effective and quick results. They help in improving the condition of patients in less time. With the recent advances in technology and the proliferation of smartphone-based applications: urinalysis is also providing effective and quick results at a lower cost. Smartphone-based applications are unique as they are autonomous and do not need a specialist to make clinical decisions. Also, changing lifestyles and technological developments are encouraging more people to opt for application-based treatment due to its easy access. This development is expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global proteinuria therapeutics market during the forecast period 2019-2023, click here.
With the presence of several major players, the global proteinuria therapeutics market is moderately fragmented. robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading proteinuria therapeutics manufacturers, that include AbbVie Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi, Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.
Also, the proteinuria therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
proteinuria therapeutics market analysis considers sales from ACE inhibitors, ARBs, and other therapeutic products. Our analysis also considers the sales of proteinuria therapeutics in Asia, Europe, North America, and ROW. In 2018, the ACE inhibitors segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the prevention of an enzyme in the body from producing angiotensin II, which narrows the blood vessels will play a significant role in the ACE inhibitors segment to maintain its market position. Also, our global proteinuria therapeutics market report looks at factors such as recent approvals and launch of advanced urinalysis diagnostic kits, increasing prevalence of associated risk factors, and growing geriatric population. However, lack of curative therapies, adverse effects of available therapeutics, and stringent regulations may hamper the growth of the proteinuria therapeutics industry over the forecast period.
Global Proteinuria Therapeutics Market: Overview
Increasing prevalence of associated risk factors
Proteinuria is a condition in which urine contains an abnormal amount of protein. This condition can be a sign of damage within the kidneys and CKD: the latter can result from diabetes as well as high blood pressure hypertension. Proteinuria can be caused by diseases that do not involve the kidneys, such as multiple myeloma and others, such as, AIDS, lupus, and rheumatoid arthritis, which also cause inflammation in the kidneys. Globally, the prevalence of all these diseases and infections is very high and is increasing continuously. This multifactorial etiology of the condition increases the demand for treatment options and, thus, drives the growth of the market at a CAGR of almost 3% during the forecast period.
Introduction of smartphone-based diagnosis and treatment
Advances in technology help in increasing the adherence of patients to treatment and, thus, obtain effective and quick results. They help in improving the condition of patients in less time. With the recent advances in technology and the proliferation of smartphone-based applications: urinalysis is also providing effective and quick results at a lower cost. Smartphone-based applications are unique as they are autonomous and do not need a specialist to make clinical decisions. Also, changing lifestyles and technological developments are encouraging more people to opt for application-based treatment due to its easy access. This development is expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global proteinuria therapeutics market during the forecast period 2019-2023, click here.
Competitive Landscape
With the presence of several major players, the global proteinuria therapeutics market is moderately fragmented. robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading proteinuria therapeutics manufacturers, that include AbbVie Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi, Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.
Also, the proteinuria therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
